Anti-relapse targeted chemoembolization as an adjunct to kidney cancer resection
https://doi.org/10.25789/YMJ.2021.73.09
Abstract
The purpose: to assess the saturation of the surgical margin of the kidney resection with a chemotherapy drug in order to determine the effectiveness of targeted balloon chemoembolization during the resection of parenchymal organ for preventing tumor recurrence.
The data obtained clearly demonstrated the prolonged fixation of the marker in the tissues of the surgical edge of the resected organ. Transarterial balloon embolization with a targeted drug for resection of the parenchymal organ may be effective for preventing tumor recurrence due to the duration of high concentrations in the surgical margin.
About the Authors
A. V. Maksimov
State Autonomous Institution of the Republic of Sakha (Yakutia) Republican Hospital No. 1 - National Center of Medicin
Russian Federation
Russian Federation
Maksimov Alexander Vasilievich - Head of the Urology Department
P. M. Ivanov
Medical Institute of the North-Eastern Federal University named after M.K. Ammosov
Russian Federation
Russian Federation
Ivanov Petr Mikhailovich - Doctor of Medical Sciences, Professor, Head of the Department of Oncology
F. G. Ivanova
State Budgetary Institution of the Republic of Sakha (Yakutia) Yakutsk Republican Oncological Dispensary
Russian Federation
Russian Federation
Ivanova Feodosia Gavrilyevna – PhD, Head of the Department of Anticancer Drug Therapy
P. A. Neustroev
Medical Institute of the North-Eastern Federal University named after M.K. Ammosov
Russian Federation
Russian Federation
Neustroev Petr Afanasyevich - PhD, Associate Professor of the Department of Hospital Surgery and Radiation Diagnostics
References
1. Banyra O.B. Angiogenesis Inhibition in Renal Cell Carcinoma (RCC) Treatment: Mechanisms, Especialities and Perspectives /Banyra O.B.,Shulyak A.V. //Experimental and Clinical Urology. – 2011. – №1. – Р. 59–68. (In Russ.)
2. European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (ETS No.123). Appendix A «Guidelines for the maintenance and care of animals». Strasbourg, 18.03.1986.
3. Kaprin A.D. Analysis of uronephrological morbidity and mortality in Russian Fede ration for 2003–2013/ Kaprin A.D., Apolikhin O.I., Sivkov A.V. // Experimental and Clinical Urology. - 2015. – № 2. – Р. 4–12. (In Russ.)].
4. Максимов А.В. Способ баллонной химиоэмболизации и резекции злокачественных опухолей паренхиматозных органов. Патент РФ на изобретение №2711549 / А.В. Максимов, П.А. Неустроев // Государственный реестр изобретений Российской Федерации. 17.01.2020.
5. Bergers G. Tumorigenesis and the angiogenic switch / G. Bergers, L.E. Benjamin // Nature Rev. Cancer. – 2003. – № 3 (6). – P. 401–410.
6. Costa J.L. Renal cell carcinima: new developments in molecular biology and potential for targeted therapies. / J.L. Costa, H.A. Drabkin // The oncologist. – 2007. – № 12. – P. 1404–15.
7. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene / N.Ferrara, K.Carver-Moore, H. Chen [et al.] // Nature. – 1996. – № 380(6573). – P. 439–42.
8. Folkman J. The vascularization of tumors / J. Folkman // Sci Am. – 1976. – № 234(5). – P. 58–64.
9. Folkman J. Fighting cancer by attacking its blood supply. / J. Folkman // Sci Am. – 1996. – № 275. – P. 150–4.
10. Gunther J.B. Bevacizumab (Avastin) for the treatment of ocular disease / J.B. Gunther, M.M. Altaweel // Survey of Ophthalmology. – 2009. - №54(3). – P. 72-400. doi: 10.1016/j.survophthal.2009.02.004
11. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endot helial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. / T. Inai, M. Mancuso, H. Hashizume [et al.] // Am. J. Pathol. – 2004. - №165(1). – P. 35-52.
12. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research / C. Kilkenny, William J. Browne [et al.] // PloS Biol. – 2010. – №8 (6). – P. 94-99.
13. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. / C.Y. Li, S. Shan, Q. Huang [et al.] // J. Nat. Cancer Inst. – 2000. – № 92(2). – P. 143–7.
14. EAU Guidelines on Renal Cell Carcinoma: 2014 Update. / B. Ljungberg, K. Bensalah, S. Canfield [et al.] // Eur. Urol. – 2015. – №67(5). – P. 913–24. doi: 10.1016/j.eururo.2015.01.005.
15. Mukherji S.K. Bevacizumab (Avastin). / S.K. Mukherji // American journal of neuroradiology. – 2009. – №31(2). – P. 235-6. doi: 10.3174/ajnr.a1987
16. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. / L.S. Rosen // Cancer Control. – 2002. – №9. – P. 36–44.
Review
For citations:
Maksimov A.V., Ivanov P.M., Ivanova F.G., Neustroev P.A. Anti-relapse targeted chemoembolization as an adjunct to kidney cancer resection. Yakut Medical Journal. 2021;(1):33-36. https://doi.org/10.25789/YMJ.2021.73.09
Views:
10
Email this article 